13:44:40 EDT Tue 25 Jun 2019
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:CLVS from 2018-06-26 to 2019-06-25 - 42 items News ReleasesIn The NewsOther
DateSymPriceTypeHeadline
2019-06-06 16:05CLVSNews ReleaseClovis Oncology Names Ginger L. Graham as New Board of Directors Chair
2019-06-01 07:30CLVSNews ReleaseExpanded Rubraca ® (Rucaparib) Data from Clovis Oncology ’s ARIEL3 and TRITON2 Trials in Ovarian and Prostate Cancers to be Presented at 2019 ASCO Annual Meeting
2019-05-20 16:05CLVSNews ReleaseClovis Oncology Presents Patient-Centered Outcomes Data from Phase 3 ARIEL3 Study for Rubraca ®? in Advanced Ovarian Cancer
2019-05-16 08:00CLVSNews ReleaseClovis Oncology Announces Presentations at 2019 ASCO Annual Meeting
2019-05-07 08:00CLVSNews ReleaseClovis Oncology Announces First Quarter 2019 Operating Results
2019-05-06 08:00CLVSNews ReleaseClovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2019
2019-05-02 08:00CLVSNews ReleaseClovis Oncology Enters into Non-Dilutive Clinical Trial Financing with TPG Sixth Street Partners for up to $175 Million
2019-04-24 16:05CLVSNews ReleaseClovis Oncology to Announce First Quarter 2019 Financial Results and Host Webcast Conference Call on May 7
2019-04-10 07:15CLVSNews ReleaseNew Research: Key Drivers of Growth for Weatherford International, J. C. Penney, SBA Communications, Clovis Oncology, Gladstone Land, and BCE — Factors of Influence, Major Initiatives and Sustained Production
2019-04-02 08:30CLVSNews ReleaseClovis Oncology Announces Interim Results from Rubraca ® (rucaparib) Phase 2 Study in Advanced Pancreatic Cancer and Nonclinical Data in Multiple Solid Tumor Types for Rucaparib and Lucitanib Presented at AACR 2019
2019-03-19 08:00CLVSNews ReleaseClovis Oncology Announces Presentations at 2019 AACR Annual Meeting
2019-03-16 12:45CLVSNews ReleaseClovis Oncology to Highlight Rubraca ® (rucaparib) Data from Post-Hoc ARIEL3 Analyses at SGO 2019 Congress
2019-03-06 16:19CLVSNews ReleaseClovis Oncology to Present at the Barclays Global Healthcare Conference
2019-03-04 03:00CLVSNews ReleaseClovis Oncology Announces Availability of Rubraca ®? (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Germany
2019-02-26 08:00CLVSNews ReleaseClovis Oncology Announces 2018 Operating Results
2019-02-22 08:00CLVSNews ReleaseClovis Oncology to Present at the 8th Annual SVB Leerink Healthcare Conference
2019-02-19 07:00CLVSNews ReleaseAlkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies
2019-02-13 07:30CLVSNews ReleaseNew Research Coverage Highlights Amicus Therapeutics, Clovis Oncology, YRC Worldwide, FORTERRA INC, Shenandoah Telecommunications, and Basic Energy Services — Consolidated Revenues, Company Growth, and Expectations for 2019
2019-02-12 08:00CLVSNews ReleaseClovis Oncology to Announce Fourth Quarter/Fiscal Year 2018 Financial Results and Host Webcast Conference Call on February 26
2019-01-24 12:28CLVSNews ReleaseClovis Oncology Announces European Commission Authorization of Rubraca ®? (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer
2019-01-07 08:00CLVSNews ReleaseClovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2018
2019-01-02 16:05CLVSNews ReleaseClovis Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference
2018-12-26 07:25CLVSNews ReleaseDetailed Research: Economic Perspectives on Canopy Growth, ArQule, MoneyGram International, Teradata, Clovis Oncology, and Axovant Sciences — What Drives Growth in Today's Competitive Landscape
2018-12-13 12:46CLVSNews ReleaseCHMP Grants Positive Opinion for New Indication of Clovis Oncology ’s Rubraca ®? (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer
2018-12-04 07:37CLVSNews ReleaseClovis Oncology Announces Positive Outcome in European Opposition Proceeding Related to Rubraca ®
2018-11-20 08:07CLVSNews ReleaseClovis Oncology Announces Second U.S. Patent Issued in Rucaparib High Dosage Strength Tablet Patent Family with Expiration in 2035
2018-11-12 07:40CLVSNews ReleaseRecent Analysis Shows Clovis Oncology, Evertec, Etsy, Ring Energy, Ocular Therapeutix, and Destination Maternity Market Influences — Renewed Outlook, Key Drivers of Growth
2018-11-07 08:00CLVSNews ReleaseClovis Oncology to Present at the Credit Suisse 27th Annual Healthcare Conference
2018-10-30 16:05CLVSNews ReleaseClovis Oncology Announces Third Quarter 2018 Operating Results
2018-10-19 06:01CLVSNews ReleaseClovis Oncology Presents Initial Results from the Ongoing Rubraca ® (rucaparib) TRITON Program in Metastatic Castration Resistant Prostate Cancer (mCRPC) at ESMO 2018 Congress
2018-10-18 09:00CLVSNews ReleaseAnalysis: Positioning to Benefit within Clovis Oncology, Destination Maternity, MSG Networks, Lindblad Expeditions, NetScout, and ANI Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
2018-10-16 08:00CLVSNews ReleaseClovis Oncology to Announce Third Quarter 2018 Financial Results and Host Webcast Conference Call on October 30
2018-10-11 16:05CLVSNews ReleaseClovis Oncology Appoints Two New Directors to its Board
2018-10-03 06:00CLVSNews ReleaseClovis Oncology to Highlight Results from Rubraca ® (rucaparib) TRITON Prostate Program at ESMO 2018 Congress
2018-10-02 08:00CLVSNews ReleaseClovis Oncology Receives Breakthrough Therapy Designation for Rubraca ® (rucaparib) for Treatment of BRCA1/2-Mutated Metastatic Castration Resistant Prostate Cancer (mCRPC)
2018-09-06 08:00CLVSNews ReleaseClovis Oncology to Present at the Morgan Stanley Global Healthcare Conference
2018-08-27 07:45CLVSNews ReleaseRecent Analysis Shows KalVista Pharmaceuticals, IZEA, Sonic Automotive, Catabasis Pharmaceuticals, ANI Pharmaceuticals, and Clovis Oncology Market Influences — Renewed Outlook, Key Drivers of Growth
2018-08-08 08:00CLVSNews ReleaseClovis Oncology Announces First Patient Enrolled in the Phase 3 ATHENA Trial
2018-08-01 16:05CLVSNews ReleaseClovis Oncology Announces Second Quarter 2018 Operating Results
2018-07-18 08:00CLVSNews ReleaseClovis Oncology to Announce Second Quarter 2018 Financial Results and Host Webcast Conference Call on August 1
2018-07-05 08:00CLVSNews ReleaseClovis Oncology Receives EMA Validation for its Application for a New Indication for Rubraca ®? (rucaparib) as Maintenance Treatment for Women with Recurrent Ovarian Cancer
2018-06-26 07:50CLVSNews ReleaseAnalysis: Positioning to Benefit within PBF Energy, Callaway Golf, Total System Services, Comcast, The Cheesecake Factory, and Clovis Oncology — Research Highlights Growth, Revenue, and Consolidated Results